Geron mit Hammernews!! (Seite 96)
eröffnet am 18.03.03 18:26:10 von
neuester Beitrag 21.03.24 13:47:21 von
neuester Beitrag 21.03.24 13:47:21 von
Beiträge: 3.090
ID: 709.348
ID: 709.348
Aufrufe heute: 0
Gesamt: 213.087
Gesamt: 213.087
Aktive User: 0
ISIN: US3741631036 · WKN: 902213 · Symbol: GERN
3,9500
USD
-3,19 %
-0,1300 USD
Letzter Kurs 02:00:00 Nasdaq
Neuigkeiten
02.05.24 · Business Wire (engl.)  |
25.04.24 · Business Wire (engl.) |
18.04.24 · Business Wire (engl.) |
03.04.24 · Business Wire (engl.) |
Werte aus der Branche Biotechnologie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 3,3000 | +70,98 | |
| 1,7850 | +42,80 | |
| 1,0700 | +31,13 | |
| 1,6500 | +29,92 | |
| 1,7500 | +27,27 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 23,390 | -16,34 | |
| 0,7500 | -16,67 | |
| 0,5305 | -17,51 | |
| 3,5000 | -26,24 | |
| 11,500 | -29,23 |
Beitrag zu dieser Diskussion schreiben
Feedback
geron hätte gut daran getan, solche pressemitteilungen zu unterlassen. der vorher generierte hype war sträflich, da dadurch zuviele shortterm longs angezogen wurden, die nun ihr material auf die straße kippen, wo bereits das blut in den rinnen läuft.
wenn vorläufiges verwirrt bzw. verwirren kann, dann sollte geron bitte enggültiges abwarten und dann berichten.
das was wir gestern erlebt haben, ist eine echte pr-pleite und recht unprofessionell.
jetzt haben wir aber genau das, was wir gar nicht wollen: UNSICHERHEIT.
zuerst die aussage 'good pharmacokinetics' -- früher hieß das im tierversuch immer 'excellent'. Was heißt denn nun good im vergleich zu excellent?
und dann noch das: 'Up to the current dose levels, no significant changes in telomerase activity or telomere length in the bulk circulating CLL cells of treated patients have been observed.'
So eine Aussage ist der reine Alptraum!!
es bedeutet zum einen: grn163l wirkt derzeit grundsätzlich nicht
zum anderen: es ist noch zu beweisen, ob es bei höheren dosen wirkt.
und zuletzt noch das problem, dass grn163l bei einem patienten wohl zu stark gewirkt hat. wie furchtbar! denn diese tatsache steht im krassen widerspruch zu der aussage, dass grn163l erst bei höhern dosen wirkt.
ich habe gestern lange nachgedacht, ob ich mich von meinem bestand trennen soll. noch bin ich leicht im plus.
ich warte nochmal ab, bin aber alles andere als amused.
uns steht eine harte zeit bevor, freunde!
wenn vorläufiges verwirrt bzw. verwirren kann, dann sollte geron bitte enggültiges abwarten und dann berichten.
das was wir gestern erlebt haben, ist eine echte pr-pleite und recht unprofessionell.
jetzt haben wir aber genau das, was wir gar nicht wollen: UNSICHERHEIT.
zuerst die aussage 'good pharmacokinetics' -- früher hieß das im tierversuch immer 'excellent'. Was heißt denn nun good im vergleich zu excellent?
und dann noch das: 'Up to the current dose levels, no significant changes in telomerase activity or telomere length in the bulk circulating CLL cells of treated patients have been observed.'
So eine Aussage ist der reine Alptraum!!
es bedeutet zum einen: grn163l wirkt derzeit grundsätzlich nicht
zum anderen: es ist noch zu beweisen, ob es bei höheren dosen wirkt.
und zuletzt noch das problem, dass grn163l bei einem patienten wohl zu stark gewirkt hat. wie furchtbar! denn diese tatsache steht im krassen widerspruch zu der aussage, dass grn163l erst bei höhern dosen wirkt.
ich habe gestern lange nachgedacht, ob ich mich von meinem bestand trennen soll. noch bin ich leicht im plus.
ich warte nochmal ab, bin aber alles andere als amused.
uns steht eine harte zeit bevor, freunde!
Ist nur eine Meinung aus dem Yahoo-Board!
Warum auch nicht?!!
GERN - first TRILLION dollar company?
12-Jun-07 12:59 pm Looks like Geron (GERN) has a cure for cancer with no side effects.
I have not heard Geron's Okarma use the term cancer "cure" until last month. It is clear that Geron's focus of cancer research has shifted from attacking just any cancer cell to focusing on the cancer stem cell as a means of defining cancer "cure."How long will it take for the media to take the lead and announce that fact. When that happens, and I am confident that it will, all hell will break loose.
Geron's drug"163L knocks down the cancer stem cell by 50% in just 3 days " Geron's Dr. Okarma said.
Geron's president Dr.Okama said he was going to make Geron the next Amgen.
If he is successful 800 shares of Geron will be worth one million dollars $$$$.
It looks like Dr.Okarma is going to far exceed his goal!!!
"If there is a company whose suite of research projects better typifies where biotechnology is headed, it isn't publicly traded."----BARRON'S 4-27-06.
Geron "It's the most valuable patent estate in all of biotechnology", says Lissa Morgenthaler.
Michael Murphy said that Geron could be the worlds first trillion $$$ company.
Warum auch nicht?!!
GERN - first TRILLION dollar company?
12-Jun-07 12:59 pm Looks like Geron (GERN) has a cure for cancer with no side effects.
I have not heard Geron's Okarma use the term cancer "cure" until last month. It is clear that Geron's focus of cancer research has shifted from attacking just any cancer cell to focusing on the cancer stem cell as a means of defining cancer "cure."How long will it take for the media to take the lead and announce that fact. When that happens, and I am confident that it will, all hell will break loose.
Geron's drug"163L knocks down the cancer stem cell by 50% in just 3 days " Geron's Dr. Okarma said.
Geron's president Dr.Okama said he was going to make Geron the next Amgen.
If he is successful 800 shares of Geron will be worth one million dollars $$$$.
It looks like Dr.Okarma is going to far exceed his goal!!!
"If there is a company whose suite of research projects better typifies where biotechnology is headed, it isn't publicly traded."----BARRON'S 4-27-06.
Geron "It's the most valuable patent estate in all of biotechnology", says Lissa Morgenthaler.
Michael Murphy said that Geron could be the worlds first trillion $$$ company.
Einige sehen das wohl auch so wie ich
No Knockout for Geron
By Melissa Davis
Senior Writer
6/12/2007 12:02 PM EDT
Click here for more stories by Melissa Davis
Fisher Investments
CyberTrader
Scottrade
TD AMERITRADE
Fidelity Investments
Charles Schwab
Geron (GERN - Cramer's Take - Stockpickr - Rating) is testing some investors' patience.
The California-based biotechnology company failed to deliver blockbuster news on its novel GRN163L cancer treatment during this week's Pan Pacific Lymphoma Conference in Hawaii. Instead, the company simply reported that GRN163L has "demonstrated good pharmacokinetics and tolerability" in patients tested during phase I/II studies so far.
GRN163L seeks to targets an enzyme, known as telomerase, that enables cancer cells to multiply and survive. At the modest doses tested thus far, however, GRN163L has failed to significantly alter telomerase activity or shorten the chromosome ends -- called telomeres -- that are involved in the cancer-development process.
Some investors seemed to be banking on an outright miracle instead. After pushing Geron toward $10 a share last month in anticipation of big news, they pounded the stock down 8.3% to $8.01 on Tuesday's modest development.
"Candidly, people don't know what to expect with Geron; that's the problem," says WBB Securities analyst Stephen Brozak. "Certainly, day traders want instant news that they can easily interpret. But this is not that simple.
"These are unique strategies that are difficult to understand and deal with."
Brozak, for one, feels that Geron continues to make steady and important progress. He has personally researched Geron for more than a decade and now sees a viable company -- with real commercial potential -- in the making. But he admits that newcomers could fail to recognize the same.
Brozak blames a potential overload of complex information for the confusion.
"It isn't like there's a shortage of news; it's like there is too much news for most investors to understand," he says. "But in fairness to the company, it's not like they're piling on with a lot of extraneous stuff. Everything they talk about has significance."
Brozak likes what he hears. He has a strong buy recommendation on Geron's stock. His firm has no position in Geron itself and has provided no investment banking services to the company over the past two years.
Meanwhile, Geron did witness some positive developments during its recent GRN163L study. For starters, the company said that one GRN163L recipient is experiencing "stable disease" patterns following two rounds of cancer treatment. Moreover, the company said that a second patient has experienced a rapid destruction in malignant cells -- with the "absolute lymphocyte count" dropping by 48% -- during a posttreatment period that has persisted for two weeks.
Geron stopped short of crediting GRN163L for progress in that patient, however, due to "the lack of measured telomerase inhibition" observed. Indeed, Geron indicated that patients should probably be exposed to GRN163L for longer periods of time in order for the treatment's telomerase-inhibiting powers to take effect.
Brozak, at least, feels more than willing to wait.
"They're starting to get some preliminary indication of how things are going," he explains. "This is one of the necessary steps in the progress that Geron is making in going from a research enterprise to a full-blown commercial operation."
No Knockout for Geron
By Melissa Davis
Senior Writer
6/12/2007 12:02 PM EDT
Click here for more stories by Melissa Davis
Fisher Investments
CyberTrader
Scottrade
TD AMERITRADE
Fidelity Investments
Charles Schwab
Geron (GERN - Cramer's Take - Stockpickr - Rating) is testing some investors' patience.
The California-based biotechnology company failed to deliver blockbuster news on its novel GRN163L cancer treatment during this week's Pan Pacific Lymphoma Conference in Hawaii. Instead, the company simply reported that GRN163L has "demonstrated good pharmacokinetics and tolerability" in patients tested during phase I/II studies so far.
GRN163L seeks to targets an enzyme, known as telomerase, that enables cancer cells to multiply and survive. At the modest doses tested thus far, however, GRN163L has failed to significantly alter telomerase activity or shorten the chromosome ends -- called telomeres -- that are involved in the cancer-development process.
Some investors seemed to be banking on an outright miracle instead. After pushing Geron toward $10 a share last month in anticipation of big news, they pounded the stock down 8.3% to $8.01 on Tuesday's modest development.
"Candidly, people don't know what to expect with Geron; that's the problem," says WBB Securities analyst Stephen Brozak. "Certainly, day traders want instant news that they can easily interpret. But this is not that simple.
"These are unique strategies that are difficult to understand and deal with."
Brozak, for one, feels that Geron continues to make steady and important progress. He has personally researched Geron for more than a decade and now sees a viable company -- with real commercial potential -- in the making. But he admits that newcomers could fail to recognize the same.
Brozak blames a potential overload of complex information for the confusion.
"It isn't like there's a shortage of news; it's like there is too much news for most investors to understand," he says. "But in fairness to the company, it's not like they're piling on with a lot of extraneous stuff. Everything they talk about has significance."
Brozak likes what he hears. He has a strong buy recommendation on Geron's stock. His firm has no position in Geron itself and has provided no investment banking services to the company over the past two years.
Meanwhile, Geron did witness some positive developments during its recent GRN163L study. For starters, the company said that one GRN163L recipient is experiencing "stable disease" patterns following two rounds of cancer treatment. Moreover, the company said that a second patient has experienced a rapid destruction in malignant cells -- with the "absolute lymphocyte count" dropping by 48% -- during a posttreatment period that has persisted for two weeks.
Geron stopped short of crediting GRN163L for progress in that patient, however, due to "the lack of measured telomerase inhibition" observed. Indeed, Geron indicated that patients should probably be exposed to GRN163L for longer periods of time in order for the treatment's telomerase-inhibiting powers to take effect.
Brozak, at least, feels more than willing to wait.
"They're starting to get some preliminary indication of how things are going," he explains. "This is one of the necessary steps in the progress that Geron is making in going from a research enterprise to a full-blown commercial operation."
Unfassbar
Die Amis strafen Geron ab. Die spinnen die Amis und verstehen nichts!!!!
Nach den Ergebnissen Geron unbedingt einsammeln!!
Es ging soch nur um siccherheitsrelevante Tests und immerhin ist bei einer Person bei einer nur zweiwöchigen Verabreichung geringer Mengen von dem Telomerasehemmer die Zahl der gefährlichen Krebszellen um 48% gesunken.
Einsammeln!!!
Die Amis strafen Geron ab. Die spinnen die Amis und verstehen nichts!!!!
Nach den Ergebnissen Geron unbedingt einsammeln!!
Es ging soch nur um siccherheitsrelevante Tests und immerhin ist bei einer Person bei einer nur zweiwöchigen Verabreichung geringer Mengen von dem Telomerasehemmer die Zahl der gefährlichen Krebszellen um 48% gesunken.
Einsammeln!!!
Geron announces its telomerase inhibitor cancer drug demonstrates 'good' pharmacokinetics and tolerability in Phase I/II trial (GERN) 8.73 : Co announces its telomerase inhibitor cancer drug, GRN163L, has demonstrated good pharmacokinetics and tolerability in its ongoing Phase I/II trial involving patients with chronic lymphocytic leukemia, according to data presented today by Alan Colowick, M.D., M.P.H., the co's president, oncology, at the Pan Pacific Lymphoma Conference in Maui, Hawaii. "Based on preclinical data demonstrating the effects of GRN163L on both mature and cancer stem cells in multiple myeloma, Geron will initiate a clinical trial involving multiple myeloma patients... In addition, the company will begin a fourth trial of GRN163L in combination with carboplatin and paclitaxel in patients with non-small cell lung cancer. The basis for this trial is the result of promising preclinical animal data demonstrating the drug's activity in this tumor type as well. Geron expects to initiate both trials in the coming months."
http://biz.yahoo.com/bw/070612/20070612005141.html?.v=1
http://biz.yahoo.com/bw/070612/20070612005141.html?.v=1
Trading Spotlight
http://biz.yahoo.com/bw/070611/20070611005188.html?.v=1
Geron says reserch indicates its embryonic stem cell-based therapeutic for spinal cord injury evades direct attack by the human immune system (GERN) 8.67 : Co announces the presentation of research studies indicating that GRNOPC1, the co's human embryonic stem cell (hESC)-based therapeutic for the treatment of spinal cord injury, evades a direct attack by the human immune system. Presented by GERN scientist Ross Okamura at the Federation of Clinical Immunology Societies meeting, the findings could mean that patients treated with GRNOPC1 would require significantly lower doses and/or shorter courses of immunosuppression than what are required for patients who undergo solid organ transplants. "The results imply that our cell-based therapeutic, unlike traditional solid organ transplants, is minimally recognized by the human immune system," said Thomas Okarma, Ph.D, M.D., GERN's president and CEO. "Because GRNOPC1 cells are allogenic, it was expected that they would be recognized and destroyed by multiple immune rejection modulators. This isn't the case. The benefit to patients is that a reduction in the requirement for immunosuppression decreases the potential for untoward side effects that are common with those types of drugs." The data indicate that GRNOPC1 cells have low susceptibility to both direct cell and antibody-mediated immune responses. The data also show that GRNOPC1 cells do not widely express non-human antigens, such as Neu5GC, that might have originated from mouse feeder cells to which the original hESC cell line was exposed in its initial derivation.
Geron says reserch indicates its embryonic stem cell-based therapeutic for spinal cord injury evades direct attack by the human immune system (GERN) 8.67 : Co announces the presentation of research studies indicating that GRNOPC1, the co's human embryonic stem cell (hESC)-based therapeutic for the treatment of spinal cord injury, evades a direct attack by the human immune system. Presented by GERN scientist Ross Okamura at the Federation of Clinical Immunology Societies meeting, the findings could mean that patients treated with GRNOPC1 would require significantly lower doses and/or shorter courses of immunosuppression than what are required for patients who undergo solid organ transplants. "The results imply that our cell-based therapeutic, unlike traditional solid organ transplants, is minimally recognized by the human immune system," said Thomas Okarma, Ph.D, M.D., GERN's president and CEO. "Because GRNOPC1 cells are allogenic, it was expected that they would be recognized and destroyed by multiple immune rejection modulators. This isn't the case. The benefit to patients is that a reduction in the requirement for immunosuppression decreases the potential for untoward side effects that are common with those types of drugs." The data indicate that GRNOPC1 cells have low susceptibility to both direct cell and antibody-mediated immune responses. The data also show that GRNOPC1 cells do not widely express non-human antigens, such as Neu5GC, that might have originated from mouse feeder cells to which the original hESC cell line was exposed in its initial derivation.
Stem cell breakthrough a bust on Wall Street
Biotechs mixed after reports of major development in stem cell research; potential treatments far, far away
http://money.cnn.com/2007/06/07/news/companies/stemcell/inde…
Biotechs mixed after reports of major development in stem cell research; potential treatments far, far away
http://money.cnn.com/2007/06/07/news/companies/stemcell/inde…
!
Dieser Beitrag wurde vom System automatisch gesperrt. Bei Fragen wenden Sie sich bitte an feedback@wallstreet-online.de
Antwort auf Beitrag Nr.: 29.443.481 von edelupolino am 23.05.07 22:20:09@ede,schau bei finanznachrichten.de nach.der chart von godmode trader vom 07.12.2006.
mfg
pedestrian
@ede,schau bei finanznachrichten.de nach.der chart von godmode trader vom 07.12.2006.mfg
pedestrian
Durchsuchen
